Could a custom vaccine slow Alzheimer's? new trial begins
NCT ID NCT05834296
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a personalized vaccine (ALZN002) made from a patient's own immune cells, designed to train the body to attack amyloid plaques in the brain. Thirty people with mild-to-moderate Alzheimer's will receive either the vaccine or a placebo. The main goal is to check safety, but researchers will also look for signs of slowing cognitive decline.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
personalized dendritic cell vaccine (ALZN002) made from the patient's own immune cells
What this could lead to
If it works, this could slow or stop Alzheimer's progression by training the immune system to clear amyloid plaques from the brain.
What could go wrong
This is a very early, small trial (30 people) testing safety first. The vaccine may not work, could cause side effects, and even if successful, it would manage the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Excellent Research Group
Doral, Florida, 33186, United States